COUR Pharma Initiates CNP-103 Clinical Trial for Newly Diagnosed Type 1 Diabetes Patients
Key Insights
COUR Pharma (search) is conducting a clinical trial evaluating CNP-103, an investigational immunotherapy treatment for type 1 diabetes (search), administered via intravenous infusion on Days 1, 8, and 90.
The study will enroll approximately 72 participants aged 12-35 years who have been diagnosed with Stage 3 type 1 diabetes (search) within the past 180 days across 40 centers in the US and Canada.
The trial is designed to assess safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-103 compared to placebo over a 208-day study period.
COUR Pharma (search) has launched a clinical trial investigating CNP-103, an investigational immunotherapy for type 1 diabetes (search) (T1D), targeting patients recently diagnosed with the autoimmune condition. The study aims to evaluate the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-103 in preserving beta cell function in newly diagnosed patients.
Trial Design and Administration
The randomized, placebo-controlled trial will administer CNP-103 or placebo through intravenous infusion on three specific timepoints: Day 1, Day 8, and Day 90. Participants will be involved in the study for approximately 208 days, which includes a screening period of up to 28 days, active study participation of approximately 90 days, and a follow-up period. Upon completion, participants will be offered enrollment in a long-term follow-up study for an additional year.
Patient Population and Enrollment
The study targets a specific patient demographic, enrolling approximately 72 participants across 40 centers in the United States and Canada. Eligible participants must be aged 12-35 years and diagnosed with Stage 3 type 1 diabetes (search) within the past 180 days, based on American Diabetes Association guidelines.
Exclusion Criteria and Prior Treatments
The trial maintains strict exclusion criteria regarding prior immunomodulatory treatments. Patients who have used oral immunomodulators such as cyclosporin, azathioprine, or methotrexate within 5 half-lives or 90 days prior to the first dose are excluded. Similarly, those who received B cell depleting immunotherapy, including rituximab, within the same timeframe are ineligible.
More extensive exclusion periods apply to other immunotherapies: T cell modifying treatments like abatacept, etanercept, and ustekinumab require a 6-month washout period, while T cell depleting immunotherapy such as teplizumab requires 12 months prior to enrollment. Patients who presented with diabetic ketoacidosis (search) at the time of diagnosis are also excluded, though mixed meal tolerance tests may be performed 2-4 weeks after DKA diagnosis.
Treatment Considerations
The study permits continued insulin use provided patients maintain a stable dose for 30 days prior to the Day 1 dose. However, other anti-diabetic agents besides insulin, such as verapamil, are prohibited within the specified timeframes. Additional immunomodulation exclusions will be determined at the discretion of the medical monitor and study site investigator.
The trial represents a targeted approach to intervening in the early stages of type 1 diabetes (search), focusing on patients within 180 days of diagnosis when significant beta cell mass may still be preserved. The multiple-dose regimen and extended follow-up period suggest the investigation of CNP-103's potential for sustained immunomodulatory effects in this autoimmune condition.